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Abstract: Cancer is a leading cause of death globally, and it is predicted and projected to 
continue rising as life expectancy increases. Although patient survival rates for some forms 
of cancers are high due to clinical advances in treatment protocols, the search for effective 
cancer vaccines remains the ultimate Rosetta Stone in oncology. Cervarix®, Gardasil®, and 
hepatitis B vaccines are currently employed in preventing certain forms of viral cancers. 
However, they are, strictly speaking, not ‘true’ cancer vaccines as they are prophylactic rather 
than therapeutic, are only effective against the oncogenic viruses, and do not kill the actual 
cancer cells. On April 2010, a new prostate cancer vaccine Provenge® (sipuleucel-T) was 
approved by the US FDA, and it is the first approved therapeutic vaccine that utilizes antigen-
presenting cell technology involving dendritic cells in cancer immunotherapy. Recent evidence 
suggests that the use of nanoscale particles like exosomes in immunotherapy could form a viable 
basis for the development of novel cancer vaccines, via antigen-presenting cell technology, to 
prime the immune system to recognize and kill cancer cells. Coupled with nanotechnology, 
engineered exosomes are emerging as new and novel avenues for cancer vaccine development. 
Here, we review the current knowledge pertaining to exosome technology in immunotherapy 
and also seek to address the challenges and future directions associated with it, in hopes of 
bringing this exciting application a step closer toward an effective clinical reality.
Keywords: exosomes, cancer vaccine, immunotherapy, nanomedicine
Introduction
Cancer is a major global cause of morbidity and mortality, and it is expected to 
rise in the coming decades.1 Conventional treatments for cancer include the use of 
  chemotherapeutic drugs, radiotherapy, and interventional surgery in the case of solid 
(and operable) tumors. Recent evidence suggests that the application of dendritic 
cell-derived exosomes (DEX), tumor cell-derived exosomes (TEX), and ascitic 
  cell-derived exosomes (AEX) could emerge as novel nanoscale immunotherapy 
  treatments for cancer, by priming the body’s immune system to recognize and kill 
cancer cells (Table 1).
Exosomes are nanoscale (50–100 nm) membrane vesicles, first described by 
Rose Johnstone in the 1970s, and it is postulated that they are involved in cell–cell 
  communication, although its exact biological function and mechanism has, to this day, 
yet to be fully elucidated.2 The canonical exosome is of intracellular origin and displays 
MHC class I and II.3 It has also been shown to contain heat shock proteins and has a 
lipid composition rich in cholesterol, sphingomyelin, and ceramide.4 Its main protein 
markers are tetraspanins (CD63, CD9), Alix, and TSG101 and is able to mediate a International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Table 1 Overview of the application of exosomes as a nanoscale cancer vaccine
Exosome  
type
Cancer type Exosome purification Exosome derivation  
and delivery
Results overview References
DeX Melanoma Centrifugation up to  
100,000 g  
30% sucrose/D2O cushion  
Treatment with PBS 
exosomal MHC–peptide  
complex pulsed with melanoma 
antigen  
CTL pulsed with  
melanoma-primed-exosomes
DC release exosomes to other  
naïve DC for T-cell priming 
exosomes require mature DC 
to promote differentiation of 
melanoma-specific effector 
T cell producing IFN-γ effector 
lymphocytes
47
AeX various Centrifugation up to  
100,000 g  
30% sucrose/D2O cushion  
Treatment with PBS
DC pulsed with AeX  
PBL stimulated with  
AeX-pulsed DC
Release of IFN-γ by PBL  
Tumor cell lysis
35
DeX Toxoplasma  
gondii
Centrifugation up to  
100,000 g  
Treatment with PBS
DeX pulsed with T. gondii- 
derived antigen
Murine models’ resistant brain  
cyst formation normally caused  
by T. gondii  
Production of T. gondii-specific 
antibody  
Increased production of cytokines
48
TeX Leukemia Centrifugation up to  
100,000 g  
30% sucrose/D2O cushion  
Treatment with PBS
Direct vaccination of murine  
models with TeX1
Inhibition of tumor growth  
CTL-induced lysis of cancer cells
34
DeX Melanoma Centrifugation up to 
100,000 g  
30% sucrose/D2O cushion  
Treatment with PBS
exosomal MHC–peptide  
complex pulsed with melanoma 
antigen  
CTL pulsed with melanoma- 
primed exosomes +  
CpG adjuvants
CpG adjuvants + exosome elicit 
immune response toward cancer 
cells
62
TeX Lymphoma  
 
Leukemia colon
Centrifugation up to  
100,000 g  
Treatment with PBS
Direct vaccination of murine  
models with TeX and heat- 
shocked TeX1
Heat-shocked TeX more  
efficacious than TEX alone 
Immune response mostly  
mediated by CTL
60
TeX Colon  
melanoma
Centrifugation up to  
100,000 g  
Sucrose gradient  
Treatment with PBS
DC pulsed with heat-shocked  
TeX
Upregulation of Th1-mediated  
tumor response
38
TeX Colon Centrifugation up to  
100,000 g  
Sucrose gradient  
Treatment with PBS
Human cancer antigen transfected 
onto murine TeX
Stimulation of immune cells 
Suppression of tumor growth
36
TeX CeA- 
expressing cells
Centrifugation up to  
100,000 g  
30% sucrose cushion 
Treatment with PBS
Direct vaccination of murine  
models with TeX and heat- 
shocked TeX1
Heat-shocked TeX confers a  
greater immunogenicity  
elicits greater immune  
response
60
DeX Leukemia Centrifugation up to  
100,000 g  
Treatment with PBS
DC pulsed with cancer cell  
antigen  
Purified exosomes used  
with cyclo-phosphamide + 
polyinosinic-polycytidylic acid
Suppression of tumor growth 
Induction of spleen cell  
proliferation and killing of  
cancer cells
49
DeX and 
TeX
Lung Centrifugation up to  
100,000 g 
Treatment with PBS
DC pulsed with cancer cells to 
obtain DeX 
TeX obtained directly from  
cancer cells
DeX elicits a greater CTL anti-
tumor response
50
DeX Lung Centrifugation up to  
100,000 g  
Treatment with PBS
DC pulsed with cancer cells CTL proliferation  
eradication of established tumors 
Long-term CTL memory
51
DeX Lung Centrifugation up to 
100,000 g  
Treatment with PBS
DC pulsed with cancer cells Intradermal more efficacious 
than subcutaneous administration 
enhanced CTL proliferation
55
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Table 1 (Continued)
Exosome  
type
Cancer type Exosome purification Exosome derivation  
and delivery
Results overview References
DeX Mesothelioma Centrifugation up to 
100,000 g  
Treatment with PBS
DC pulsed with tumor cell line 
lysate
Antitumor immunity with 
prolonged murine model survival 
Resistance of secondary tumor 
challenge
53
TeX Pancreatic Centrifugation up to 
200,000 g  
Treatment with PBS
Interaction of exosomal 
nanoparticles with pancreatic  
cancer cells induces apoptosis
Induction of apoptosis in  
cancer cells via notch signaling
41
TeX Pancreatic Centrifugation up to 
200,000 g  
Treatment with PBS
Interaction of exosomal 
nanoparticles with pancreatic  
cancer cells induces apoptosis
Induction of apoptosis in cancer  
cells via PI3K/Akt/GSK-3β  
survival pathway
42
DeX Melanoma Centrifugation up to 
100,000 g  
30% sucrose/D2O cushion 
Treatment with PBS
DC pulsed with cancer cells 
Addition of cyclo-phosphamide
Antigen-dependent antitumor  
effects against pre-existing tumors  
via CD4+ and CD8+ T cells
52
TeX vSv Centrifugation  
Treatment with PBS
Incorporation of vSv antigen  
onto exosome  
DC pulsed with vSv–exosome 
complex
Increased IgG antibody response 
expansion of CTL  
Protection from challenge  
with ovalbumin expressing  
tumor cells
44
DeX Melanoma Centrifugation up to 
100,000 g  
30% sucrose/D2O cushion 
Treatment with PBS
DC pulsed with cancer cells IL-15Rα-dependent cell  
proliferation  
NKG2D-dependent NK  
cell activation
54
TeX Mesothelioma Centrifugation up to  
100,000 g  
Sucrose gradient  
Treatment with PBS
DC pulsed with TeX Transfer of tumor antigen to DC  
Induction of CTL-dependent 
antitumor effect
43
TeX Melanoma Centrifugation up to  
100,000 g  
Treatment with PBS
TeX engineered to display 
membrane-bound HSP70  
DC pulsed with engineered TeX
CTL-mediated antitumor 
immunity  
NK cell-mediated antitumor 
immunity  
Membrane-bound HSP70  
TEX more efficacious than 
cytoplasmic HSP70 TeX
39
TeX Lymphoma Centrifugation up to 
100,000 g  
30% sucrose cushion
TeX coated with SeA-TM domain 
Direct vaccination of modified  
TeX into murine models1
Inhibition of tumor growth 
Increased antigen-specific  
cytokine secretion by  
T cells  
SeA-TM-coated TeX elicits  
a more potent immune response
59
TeX OvA-expressing  
tumor cells
Centrifugation up to  
100,000 g  
30% sucrose cushion
TeX with IL-2 genetic  
modification  
Direct vaccination of modified  
TeX into murine models1
Induction of antigen-specific 
Th1-polarized immune response 
Activation of CD4+ and CD8+  
T cells  
Activation of NK cells  
IL-2 genetic modification  
elicits a more potent  
immune response
45
TeX Fibrosarcoma 
OvA-expressing 
tumor cell lines
Centrifugation up to 
100,000 g
Incorporation of tumor antigen 
onto TeX Direct vaccination of 
murine models1
More potent immune response 
toward vesicle-bound antigen  
than soluble antigen  
Mode of secretion can determine 
immunogenicity
40
DeX Adenocarcinoma Centrifugation up to 
100,000 g  
Treatment with PBS
DC pulsed with tumor peptide 
Direct vaccination of murine 
models1
Priming of CTL  
eradication and inhibition of 
established tumors
46
Note: 1In vivo study.
Abbreviations: PBS, phosphate-buffered saline; SeA-TM, enterotoxin A hydrophobic trans-membrane domain; CeA, carcinoembryonic antigen; DC, dendritic cell; CTL, 
cytotoxic T lymphocytes; PBL, peripheral blood leukocytes.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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biological immune response by activating T lymphocytes (via 
antigen presentation), natural killer (NK) cells (via NKG2D 
ligand binding), and dendritic cells (via antigen transfer).5 
The understanding of exosome biology has increased expo-
nentially in recent years, leading to the creation of online 
databases such as Exocarta,6 an encyclopedia dedicated to 
providing original research findings about exosomes and 
their associated proteins.7
The advent of nanotechnology has generated an immense 
interest among researchers in its application to medicine. 
A major goal of the utilization of nanoscale drug delivery 
systems is to improve its therapeutic index by increasing its 
potency at specific sites while simultaneously reducing sys-
temic toxicity.8 Nanoscale drug delivery systems approved by 
the US Food and Drug Administration in cancer treatments 
are currently available, for example, Doxil® (doxorubicin 
encapsulated in liposomes)9 and Abraxane® (paclitaxel 
attached to nanoparticles).10 In addition to being novel drug 
delivery systems, nanoscale particles can also be specifically 
engineered to stimulate the immune system, which could 
form an attractive basis for cancer vaccine development.11 
There is increasing evidence that nanoscale particles, for 
example, recombinant virus-like particles (VLPs), inert nano-
beads, and immunostimulating complexes, are being utilized 
in cancer vaccine development due to their effectiveness at 
eliciting cellular and humoral immune responses.12 It has been 
demonstrated that synthetic nanoparticles could be con-
jugated to biological molecules (eg, exosomes) and could 
potentially be used as an effective vaccine delivery system.13 
Furthermore, there is a growing interest in the utilization of 
biological molecule delivery systems that serve as conduits 
to deliver genetic material, drug, or antigen into the body, 
and attractive candidates are liposomes, VLPs, erythrocyte 
ghosts, and exosomes (Figure 1).14
Thus in this review, we seek to discuss the evidence per-
taining to the use of exosomes as a cell-free (hence, conferring 
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Figure 1 Biological delivery systems. A) Bacteria can be used for gene delivery, and it is used in cancer gene therapy, DNA vaccination, and treatment of some genetic 
diseases. B) Bacteriophages are viruses that infect bacteria, and they can be genetically engineered and introduced into bacteria for genetic replication. C) virus-like particles 
(vLPs) can be engineered from plasmids coding for viral structure proteins. These vLPs can then be linked to antigens and introduced into the body to elicit an immune 
response. D) erythrocyte ghosts are red blood cells that have their cytoplasmic contents removed, and they can be used as vehicles for drug delivery. E) exosomes are 
nanoscale vesicles released from dendritic cells and tumor cells, and they can be purified and loaded with antigens and introduced into the body to elicit a cell-specific anti-
tumor response. Copyright © 2009, Nature Publishing Group. Reproduced with permission from Seow Y, wood MJ. Biological gene delivery vehicles: beyond viral vectors. 
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a low immunogenicity and high biosafety profile) nanoscale 
cancer vaccine and also to explore the potential of combining 
it with nanotechnology in the hopes of bringing the concept 
of immunotherapeutic cancer vaccines toward a viable and 
feasible clinical reality.
The search for a cancer vaccine
Significant clinical advances have been made in the treat-
ment of cancer using the immune system. One of the best 
examples of this is the use of donor lymphocyte infusions, 
which is useful in treating chronic myeloid leukemia.15 
Bone marrow transplantation has also revolutionized the 
way hematological malignancies are treated.16 However, 
the search for a true cancer vaccine remains largely elusive. 
Using cervical cancer as a prime example, current (prophy-
lactic) treatment involves vaccination with either Cervarix® 
or Gardasil®, which are developed from and based on VLP 
technology, and is useful against cancer-causing variants of 
human papillomavirus (HPV).17 A modified strategy using 
long synthetic HPV oncopeptides has demonstrated that both 
CD8+ and CD4+ T-cell responses can be mounted in vivo and 
are capable of inducing complete remission in some patients 
with vulvar cancer.18 These results are very encouraging as, 
for the first time, an antiviral/tumor vaccine has successfully 
eradicated established tumors. However, these approaches 
are not ‘true’ cancer vaccines as an antiviral response is 
what kills the tumor. In the relentless pursuit of a true 
cancer vaccine, interesting approaches have been adopted 
by targeting ‘self’ proteins on cells that are only expressed 
at particular sites at specific time frames.19 Although these 
approaches have shown very promising results in murine 
models, their applicability to humans remain to be seen. In 
addition, the hepatitis B vaccine protects against hepatitis B 
virus, which is associated with liver cancer.20 Until recently, 
these so-called ‘cancer vaccines’ protect against viruses 
and are prophylactic (must be administered before the viral 
infection) rather than therapeutic because they do not kill 
the actual cancer cells.
On April 2010, the Food and Drug Administration 
approved the use of Provenge® (sipuleucel-T) in the   treatment 
of advanced prostate cancer – the first ‘true’ therapeutic 
  cancer vaccine that stimulates the body to kill cancer cells by 
eliciting a biological immune response.21 This involves puls-
ing dendritic cells with prostatic acid phosphatase-  containing 
fusion protein in order to prime the immune system to 
  recognize and kill prostate cancer cells.22 In terms of clinical 
trials in cancer vaccine development in the European Union 
and United States,23 this technique of pulsing dendritic cells 
with cancer antigen bears stark similarity with the clinical 
trials involving exosomes reviewed here, and therefore gives 
credence to the proof-of-concept that the application of exo-
some could be used as a nanoscale cancer vaccine.
Mounting evidence demonstrates that loading/pulsing 
dendritic cells with tumor antigens (or TEX) results in 
higher response rates in cancer patients in terms of eliciting 
an antitumor-specific immunity, compared to other types 
of vaccine formulations (eg, peptide vaccines and viral 
vector vaccines).24 This could well form a cornerstone by 
which cancer vaccines could be effectively developed in 
the future.
Cancer immunotherapy
For a cell to become cancerous, it must typically gain an 
oncogenic function (such as among many others, Myc, 
Bcl-2, and Ras, which promote cell proliferation), lose its 
tumor suppressor function (such as p53 and Rb, which pro-
mote cell arrest), and be immortalized.25 Within the tumor 
microenvironment, there is extensive interaction between 
cancer cells and immune cells, and cancer cells may escape 
immune   surveillance by aberrant expression of antigen 
presentation (eg, lack of MHC I), absence of costimulatory 
molecules (eg, lack of B7 molecules), and release of immu-
nosuppressive factors (eg, IL-10 and TFGβ).26 However, 
the ubiquitous question of why and how the immune system 
tolerates cancer cells in the first place remains poorly under-
stood and has generated a relentless pursuit toward a search 
for an immunotherapeutic cancer vaccine.
Dendritic cells (or, more accurately, interdigitating 
  dendritic cells) are professional antigen-presenting cells 
(APCs), which would be activated upon encountering a for-
eign agent and would interact with T cells to elicit an antigen-
specific immune response.27 When immature dendritic cells 
are activated upon stimulation by foreign antigens, they 
become mature dendritic cells, which are powerful APCs, 
priming naïve lymphocytes as well as releasing chemokines 
to attract T cells (Figure 2).24 In contrast to using monoclo-
nal antibodies in cancer immunotherapy, which is notori-
ous for its systemic side effects like immunosuppression 
and hypersensitivity reactions due to by stander effects,28 
dendritic cell-based immunotherapy could function as an 
attractive alternative for cancer treatment as the immune 
response mounted is more specific.29 Recent evidence shows 
that artificial APC systems are also emerging as powerful 
techniques for immunotherapy, and the superior biosafety 
profile of exosomes has made them an attractive candidate 
for cancer vaccine development.30International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 2 Different functions of immature and mature dendritic cells. A) In the 
absence of inflammation and costimulation, antigen presentation to immature den-
dritic cells induces tolerance or anergy (lack of an immune response). This results 
in deletion or induction of a regulatory phenotype of T cells. B) In the presence 
of inflammation, immature dendritic cells become activated into mature dendritic 
cells. Antigen presentation in the presence of costimulatory molecules causes clonal 
expansion of CD4+ (helper) and CD8+ (cytotoxic) T cells and activation of B cells 
to produce antibodies and NK cells. Copyright © 2005, Nature Publishing Group. 
Reproduced with permission from Banchereau J, Palucka AK. Dendritic cells as 
therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296–306.
A nanoscale and cell-free  
cancer vaccine
An ideal cancer vaccine should be able to prime the immune 
system to recognize specific tumor antigen and then mount 
an appropriate immune response toward cancer cells without 
causing ‘by stander effect’ damage to neighboring cells.31 
Evidence for such a vaccine remains few and far between, 
and clinical trials involving cancer vaccines usually yield 
less-than-satisfactory results, for example, MyVax® and 
FavId®, which were hailed as ‘personalized’ vaccines for 
treating non-Hodgkin’s lymphoma, failed to demonstrate 
any significant therapeutic response.32 Although Provenge® 
represents a milestone in cancer vaccine development, the 
modest increase in survival time (4.1 months) and the exor-
bitant cost per patient (about US$93,000) for three doses of 
the vaccine demonstrate a need to find novel yet economical 
ways of cancer vaccine treatment.33
Exosomes interact extensively with cells of the immune 
system, and it has been shown that they activate dendritic 
cells, thereby priming the immune system to recognize and 
kill cancer cells (Figure 3).5 Exosomes are typically derived 
and purified using a series of centrifugation steps, not exceed-
ing 100,000 g on a 30% D2O sucrose cushion.34 AEX taken 
from peritoneal cavity fluid in cancer patients have been 
shown to cause tumor cell lysis by inducing dendritic cells 
to prime T lymphocytes via an MHC I-dependent pathway 
to kill cancer cells and also triggers the release of IFN-γ 
by peripheral blood lymphocytes in in vitro experimental 
models (Figure 4).35
Similarly, TEX are exosomes purified from cancerous 
cells. TEX contains tumor antigens, and they have been 
shown to stimulate cells of the immune system and reduce 
tumor growth.36 There is also evidence pointing toward TEX 
as tumor and RNA transporters, which could serve as a useful 
biomarker and diagnostic tool (Figure 5).37 It has been shown 
that TEX expressing heat shock protein-70 (Hsp70) upregu-
lates T helper cell 1 (Th1)-mediated tumor response.38 Further-
more, it has also been reported that membrane-bound Hsp70 
TEX are more efficacious than cytoplasmic Hsp70 TEX.39 
Evidence indicates that more potent immune responses are 
mounted toward vesicle-bound antigen compared to soluble 
antigen, and the mode of secretion can determine immu-
nogenicity.40 Interestingly, induction of apoptosis in cancer 
cells via notch signaling41 and PI3K/Akt/GSK-3β survival 
pathways42 is observed when TEX interacts with pancreatic 
cancer cells. Apart from stimulating the adaptive immune 
system by cross-priming cytotoxic T cells,43 it has also been 
demonstrated that TEX can activate the innate immune system 
by increasing IgG antibody response44 and NK cells.45
When dendritic cells are pulsed with cancer antigens 
or tumor peptides,46 DEX has been shown to elicit stronger 
immune responses toward cancer cells,47 with upregulation 
of specific antibody release and cytokine production.48 It has 
also been shown that DEX suppresses tumor growth49 and 
eradication of established tumors50 by CD8+ T cells51 and CD4+ International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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T cells,52 as well as breaking tolerance completely by resistance 
to secondary tumor challenge.53 Furthermore, it has also been 
reported that NK cells are involved in the immune response 
toward cancer cells via NKG2D-dependent NK cell activation 
and IL-15Rα-dependent cell proliferation.54 In terms of the 
mode of delivery, it has been shown that intradermal injection 
of DEX is more efficacious than subcutaneous, leading to 
suggestions that there might be more dendritic cells in the 
intradermal area than subcutaneous area.55
To date, three Phase I clinical trials (China, France, 
and the United States) have been conducted, involving 
the application of exosomes to elicit immune responses 
against established tumors (Table 2). Dai et al56 reported 
that using AEX in patients with colorectal cancer induces 
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Figure 3 Interactions of exosomes and other nanoscale vesicles with cells of the immune system. A) A variety of cells secrete exosomes, and it can activate different types of immune 
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tumor antigen-specific cytotoxic T-cell responses, with none 
to minimal side effects, and is well tolerated by patients. 
Escudier et al57 demonstrated the feasibility of scaling up 
and purification of clinical grade DEX using good manu-
facturing practice and restored the number and NKG2D-
dependent function of NK cells in patients with melanoma 
(Figure 6).54 Furthermore, a study by Morse et al58 indicates 
a MAGE-specific T cell response and increased NK lytic 
activity in patients with non-small cell lung carcinoma with 
the use of DEX.
Challenges and future directions
Although it has been established from the results in clinical 
trials that exosomes can be safely administered, their 
potency in terms of eliciting appropriate immune responses 
to kill cancer cells leaves much to be desired. The small 
number of patients involved in the clinical trials calls into 
question the statistical significance of the results. Most of 
the experimental evidence reviewed here revolves around 
solid tumors, and it has not been sufficiently demonstrated 
that non solid tumors (eg, hematological malignancies) can 
be treated using exosome technology. Furthermore, taking 
into account that exosomal immunotherapy relies heavily 
on the immune system, there remains a need to address the 
issue of cancer patients who are immunocompromised and/
or immunosuppressed due to chemotherapy and radiother-
apy regimens and therefore might not be able to sufficiently 
surmount cancer cells with their immune system alone.
Understandably, the next major goal is to increase the 
biological magnitude of the immune response, and this could 
be achieved perhaps by artificially coating and engineering 
exosomes59 with tumor antigens to make it more recogniz-
able to the immune system. It has also been shown that 
heat-shocked TEX are more efficacious than TEX alone,60 
as it confers a greater immunogenicity and elicits a greater 
immune response,61 thereby potentially making it a more 
effective cancer vaccine. It has also been shown that when 
CpG adjuvants are added alongside exosome therapy, naïve 
T cells are more effectively primed.62
The application and potential of nanotechnology in medi-
cine heralds a beginning of a new chapter in the treatment of 
human diseases. Carbon nanotubes (CNTs) are allotropes of 
carbon, and research reveals that it not only has the potential 
for imaging and treating cancer cells, it can also be utilized in 
cancer vaccine delivery systems (Figure 7).63 There is   evidence 
to suggest that CNTs, when conjugated to tumor antigens, 
elicits a specific antitumor response in animal   models.64 
Furthermore, it has been shown that   peptide-functionalized 
CNTs can function as efficient vaccine delivery systems 
which trigger specific antibody responses.65 In addition, it has 
been experimentally demonstrated that ex vivo clonal expan-
sion of T cells with antibody-linked CNTs results in T-cell 
activation and might prove to be a novel immunotherapy 
technique.66 There are currently no studies that explore the 
concept of combining CNTs with exosomes, and this could 
perhaps function as a novel technique for cancer vaccine 
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Figure  4  The  therapeutic  application  of  AeX.  Dendritic  cells  from  peripheral 
blood monocytes are pulsed with AEX, and cell-specific anti tumor response has 
been  observed.  Copyright  ©  2002,  elsevier.  Reproduced  with  permission  from 
Andre F, Schartz Ne, Movassagh M, et al. Malignant effusions and immunogenic 
tumour-derived exosomes. Lancet. 2002;360(9329):295–305.
Figure 5 Exosomes are observed on the surface of glioblastoma cells. Tumor-specific 
peptides or antigens from TEX can be purified and pulsed onto dendritic cells for 
immunotherapy. Copyright © 2008, Nature Publishing Group. Reproduced with 
permission from Skog J, wurdinger T, van Rijn S, et al. Glioblastoma microvesicles 
transport RNA and proteins that promote tumour growth and provide diagnostic 
biomarkers. Nat Cell Biol. 2008;10(12):1470–1476.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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development. Quantum dots (QDs) are also emerging as novel 
fluorescent probes for imaging and tracking the behavior 
of cells and nanoscale particles.67 QDs are semiconductor 
nanocrystals of about 2–10 nm capable of fluorescing at a 
greater intensity and are more photostable than conventional 
chromophores.68 Considering that exosomes are nanoscale 
spherical objects, it might also be possible to encapsulate or 
tether QDs with exosomes in order to image and track their 
progress in killing cancer cells.69 Theoretically, it might also 
be possible to engineer QDs to fluoresce at different colors 
to indicate different biological events, and this could be use-
ful in monitoring the interactions of exosomes with T cells, 
NK cells, and dendritic cells in order to better understand its 
antitumor mechanism.70 Indeed, it has been experimentally 
demonstrated that using nanotechnology, exosomes can 
be engineered to bear an optimal number of MHC I and 
ligands that would activate T cells, and its in vivo activity 
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Figure 6 Clinical grade exosomes in immunotherapy. The process of how DeX can 
be derived, purified, and utilized in cancer treatment. Creative Commons. Reproduced 
with permission from  escudier B, Dorval T, Chaput N, et al. vaccination of metastatic 
melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the 
first phase I clinical trial. J Transl Med. 2005;3(1):10.
Table 2 The application of exosomes as a cancer vaccine in Phase I clinical trials
Cancer type No. of 
patients
Exosome 
type
Results References
Colorectal 54 AeX Detection of DTH 
Induction of tumor-specific antitumor CTL response 
AeX + GM-CSF shows higher efficacy
56
Melanoma 15 DeX Demonstrated feasibility of large-scale GMP exosome production 
well tolerated in patients with no major toxicity 
Restoration of number and NKG2D-dependent 
function of NK cells
57, 54
NSCLC 13 DeX Demonstrated feasibility of large-scale exosome production 
well tolerated in patients with no major toxicity 
Stability of disease and activation of immune effectors
58
Abbreviations: CTL, cytotoxic T lymphocytes; GM-CSF, granulocyte-macrophage colony-stimulating factor.
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Figure 7 Carbon nanotubes in cancer immunotherapy.  A) Pristine CNT is the default setting 
of CNT, which lacks any bioconjugation or biofunctionalization. They have a strong tendency 
to aggregate and are mostly used in studies to assess nanotoxicity. B) PeG-conjugated CNT 
can be used in systemic cancer imaging. C) Copolymer or surfactant-coated CNT with PeO 
or PPO, and it can be used in localized cancer imaging. D) ssDNA-coated CNT, which aids 
dispersion and separation. E) Chemically functionalized (covalent surface modification) CNT 
by 1,3 dipolar cycloaddition. F) Chemically functionalized (covalent surface modification) 
CNT by acid oxidation. Copyright © 2009, Nature Publishing Group. Reproduced with 
permission from Kostarelos K, Bianco A, Prato M. Promises, facts and challenges for 
carbon  nanotubes  in  imaging  and  therapeutics.  Nat  Nanotechnol.  2009;4(10):627–633. 
Abbreviations:  CNT,  carbon  nanotube;  PeG,  lipid-polyethylene  glycol;  PeO, 
polyethylene oxide; PPO, polypropylene oxide; ssDNA, single-stranded DNA.
can be traced by encapsulating superparamagnetic iron oxide 
nanoparticles (Figure 8).71 Exosomes can also carry cytok-
ines, DNA, RNA, adjuvants, labels, costimulatory signals, 
and gene therapy vectors, which makes it the ultimate Trojan 
horse. Therefore, engineering the production of exosomes 
using nanotechnology embodies what we believe is the new 
platform for cancer vaccines of the future.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 8 Interaction of engineered exosomes with cells of the immune system. A) engineered exosomes (red small circles) coated with A2*MHC class I molecules bound to 
CMv peptides do not bind CD8+ T cell (stained green) from a CMv positive donor who is HLA A2 negative, showing that exosomes do not bind randomly to T cells and that 
binding is very much MHC dependant. B) However, when the same exosomes carrying A2*MHC/CMv complexes are cocultured with T cell from a CMv+ and A2+ donor, 
direct interaction between exosomes and CD8+ T cells is clearly seen. C) engineered exosomes (stained red) also bind to natural APCs (stained green and orange when the 
red and green color overlaps). This figure shows a natural APC activating three different CD8 T cells via engineered exosomes. D) exosomes bind to APC naturally whether 
they are engineered or not as the lipids themselves are the binding sites. Copyright © 2009, Nature Publishing Group. de La Pena H, Madrigal JA, Rusakiewicz S, et al. Artificial 
exosomes as tools for basic and clinical immunology. J Immunol Methods. 2009;344(2):121–132.
Conclusion
The application of immunotherapy represents a new paradigm 
in cancer treatment development. The utilization of exosomes 
in APC systems involving dendritic cells are emerging as 
powerful techniques to prime the immune system in order 
to recognize and suppress cancer cell proliferation as well 
as eradicating established tumors. Despite the modest results 
of the Phase I clinical trials, the potential for and advance-
ment of the application of exosomes as a nanoscale cancer 
vaccine are very real. Therefore, larger multicenter clinical 
trials are needed in order to establish the efficacy of exo-
somes, and more research has to be conducted to elucidate 
its mechanism of interaction with the immune system in 
order to improve its potency. Finally, coupling the use of 
exosomes with nanotechnology will most likely form the 
basis where novel nanoscale cancer vaccines will be devel-
oped in the future. Taken together, the current literature and 
the growing body of evidence indicate that exosomes could 
indeed be utilized as a novel nanoscale and cell-free cancer 
vaccine, and more research into this area is not only worth 
pursuing but paramount.
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